{"id":"W3213958873","doi":"10.1182/blood-2021-153189","title":"Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with <i>FLT3</i> or <i>CBL</i> Mutations","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Medicine; Tolerability; Hypomethylating agent; Myelodysplastic syndromes; Internal medicine; Phases of clinical research; Decitabine; Oncology; Clinical trial; Adverse effect; Bone marrow; Biology; Genetics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001220963,0.001134668,0.002071351,0.0003467018,0.0005659123,0.0007852322,0.0006932456,0.001087475,0.00255198],"category_scores_gemma":[0.0006666991,0.0005348368,0.0009587905,0.0003024297,0.0006983372,0.000573852,0.0002185461,0.002682386,0.0006436828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007613385,"about_ca_system_score_gemma":0.001521678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001076097,"about_ca_topic_score_gemma":0.003438895,"domain_scores_codex":[0.99965,0.0001439449,0.0000227411,0.00006903049,0.00003081613,0.00008340153],"domain_scores_gemma":[0.9994724,0.00009402219,0.00006118281,0.00004309533,0.00005344364,0.0002756917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4533158,0.1763001,0.01472477,0.001597885,0.002527925,0.0009629362,0.0007350027,0.006755164,0.1882946,0.0005404226,0.007851522,0.1463939],"study_design_scores_gemma":[0.3392504,0.6147696,0.0218668,0.00005912863,0.00100221,0.0006921016,0.00006173063,0.001256414,0.01588111,0.0001689442,0.00495039,0.00004128233],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878169,0.002719704,0.0007530542,0.0004897589,0.00009790877,0.003981913,0.001524625,0.0001027048,0.002513487],"genre_scores_gemma":[0.9890223,0.001486991,0.00167575,0.000665735,0.00009564252,0.002357998,0.002602097,0.00002183361,0.002071771],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00255198,"threshold_uncertainty_score":0.008537173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01605461880834419,"score_gpt":0.2932478424579282,"score_spread":0.277193223649584,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}